Regulatory and other rheumatoid factors in rheumatoid arthritis patients with active disease or in remission.
disease activity
pathological rheumatoid factor
regulatory rheumatoid factor
rheumatoid arthritis
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
15
11
2021
received:
22
06
2021
accepted:
09
12
2021
pubmed:
26
12
2021
medline:
1
4
2022
entrez:
25
12
2021
Statut:
ppublish
Résumé
Previously, we identified a regulatory rheumatoid factor (regRF), the production of which provides rats with resistance to collagen-induced arthritis (CIA). Immunization with conformers of IgG Fc fragments carrying epitopes specific to regRF reduces symptoms of CIA. The aim of this study was to determine whether there is a link between regRF levels and rheumatoid arthritis (RA) activity in humans in order to assess the potential of regRF as a therapeutic biotarget in RA. The variability of rheumatoid factor (RF) specificities present in the blood of RA patients was also studied. The regRF were studied in RA patients with active disease and in remission. Variability in the specificities of RF associated with RA was studied by concurrent inhibition of RF latex fixation by variants of modified IgG. Patients in remission had regRF levels higher than in healthy subjects. The regRF in remission was characterized by tight binding to its antigen, as in healthy subjects. The regRF levels in patients with active RA varied dramatically, and regRF binding to its antigen was weak. The exacerbation of Still's disease coincided with low regRF levels and affinity, while an improvement in patient condition was associated with an increase in regRF levels and affinity. The RF specific to RA, which was detected by the RF latex-fixation method, was a nonhomogeneous population of antibodies that included RF to lyophilized IgG, to IgG immobilized on polystyrene, and to rabbit IgG. Stimulating regRF production might enable improved RA therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Previously, we identified a regulatory rheumatoid factor (regRF), the production of which provides rats with resistance to collagen-induced arthritis (CIA). Immunization with conformers of IgG Fc fragments carrying epitopes specific to regRF reduces symptoms of CIA. The aim of this study was to determine whether there is a link between regRF levels and rheumatoid arthritis (RA) activity in humans in order to assess the potential of regRF as a therapeutic biotarget in RA. The variability of rheumatoid factor (RF) specificities present in the blood of RA patients was also studied.
METHODS
METHODS
The regRF were studied in RA patients with active disease and in remission. Variability in the specificities of RF associated with RA was studied by concurrent inhibition of RF latex fixation by variants of modified IgG.
RESULTS
RESULTS
Patients in remission had regRF levels higher than in healthy subjects. The regRF in remission was characterized by tight binding to its antigen, as in healthy subjects. The regRF levels in patients with active RA varied dramatically, and regRF binding to its antigen was weak. The exacerbation of Still's disease coincided with low regRF levels and affinity, while an improvement in patient condition was associated with an increase in regRF levels and affinity. The RF specific to RA, which was detected by the RF latex-fixation method, was a nonhomogeneous population of antibodies that included RF to lyophilized IgG, to IgG immobilized on polystyrene, and to rabbit IgG.
CONCLUSION
CONCLUSIONS
Stimulating regRF production might enable improved RA therapy.
Identifiants
pubmed: 34952993
doi: 10.1002/jcla.24187
pmc: PMC8841179
doi:
Substances chimiques
Immunoglobulin G
0
Rheumatoid Factor
9009-79-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24187Subventions
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 0827-2020-00
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 12
Informations de copyright
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Arthritis Rheum. 2011 Mar;63(3):573-86
pubmed: 21294106
Ann N Y Acad Sci. 1986;475:106-13
pubmed: 2431641
Int J Rheum Dis. 2015 May;18(4):408-20
pubmed: 24666434
J Clin Lab Anal. 2022 Feb;36(2):e24187
pubmed: 34952993
Immunobiology. 2010 Dec;215(12):963-70
pubmed: 20163888
Clin Exp Immunol. 2001 Mar;123(3):496-504
pubmed: 11298139
Int J Biol Macromol. 2017 Feb;95:938-945
pubmed: 27984139
Endocr Metab Immune Disord Drug Targets. 2018;18(6):596-601
pubmed: 29521254
Scand J Rheumatol Suppl. 1988;75:164-71
pubmed: 3238350
J Clin Lab Anal. 2020 Dec;34(12):e23533
pubmed: 32789896
PLoS One. 2019 Jun 14;14(6):e0217624
pubmed: 31199818